Skip to main content
NCBI home page
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 1980 Sep-Oct;53(5):361–366.

Acute cardiac failure and hepatic ischemia induced by disopyramide phosphate.

S J Scheinman, D S Poll, S Wolfson
PMCID: PMC2595921  PMID: 7222741

Abstract

Two patients abruptly developed congestive heart failure and elevation in serum transaminase levels when given disopyramide phosphate; enzyme abnormalities and hemodynamic status corrected upon withdrawal of the drug. Both patients had underlying ischemic cardiomyopathy. Myocardial infarction, pulmonary embolism, and viral hepatitis were ruled out in both patients. One patient had a liver biopsy documenting central hepatic necrosis with congestion, consistent with hepatic ischemia and not toxic hepatitis. In the other patient, cardiac decompensation and hepatocellular enzyme elevation were reproduced on rechallenge with the drug. Disopyramide should be used with caution in patients with heart failure.

Full text

PDF
361

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bloth B., de Faire U., Edhag O. Extreme elevation of transaminase levels in acute heart disease-a problem in differential diagnosis? Acta Med Scand. 1976;200(4):281–288. doi: 10.1111/j.0954-6820.1976.tb08232.x. [DOI] [PubMed] [Google Scholar]
  2. Cohen J. A., Kaplan M. M. Left-sided heart failure presenting as hepatitis. Gastroenterology. 1978 Mar;74(3):583–587. [PubMed] [Google Scholar]
  3. Danilo P., Jr, Rosen M. R. Cardiac effects of disopyramide. Am Heart J. 1976 Oct;92(4):532–536. doi: 10.1016/s0002-8703(76)80054-3. [DOI] [PubMed] [Google Scholar]
  4. FRUMIN A. M., MENDELL T. H., MINTZ S. S., NOVACK P., FAULK A. T. Nucleated red blood cells in congestive heart failure. Circulation. 1959 Sep;20:367–370. doi: 10.1161/01.cir.20.3.367. [DOI] [PubMed] [Google Scholar]
  5. Hulting J., Rosenhamer G. Hemodynamic and electrocardiographic effects of disopyramide in patients with ventricular arrhythmia. Acta Med Scand. 1976;199(1-2):41–51. doi: 10.1111/j.0954-6820.1976.tb06689.x. [DOI] [PubMed] [Google Scholar]
  6. Koch-Weser J. Disopyramide. N Engl J Med. 1979 Apr 26;300(17):957–962. doi: 10.1056/NEJM197904263001705. [DOI] [PubMed] [Google Scholar]
  7. Mathur P. P. Cardiovascular effects of a newer antiarrhythmic agent, disopyramide phosphate. Am Heart J. 1972 Dec;84(6):764–770. doi: 10.1016/0002-8703(72)90069-5. [DOI] [PubMed] [Google Scholar]
  8. Meinertz T., Langer K. H., Kasper W., Just H. Disopyramide-induced intrahepatic cholestasis. Lancet. 1977 Oct 15;2(8042):828–829. doi: 10.1016/s0140-6736(77)90768-1. [DOI] [PubMed] [Google Scholar]
  9. Podrid P. J., Schoeneberger A., Lown B. Congestive heart failure caused by oral disopyramide. N Engl J Med. 1980 Mar 13;302(11):614–617. doi: 10.1056/NEJM198003133021106. [DOI] [PubMed] [Google Scholar]
  10. Riccioni N., Bozzi L., Susini N., Roni P. Disopyramide-induced intrahepatic cholestasis. Lancet. 1977 Dec 24;2(8052-8053):1362–1363. doi: 10.1016/s0140-6736(77)90417-2. [DOI] [PubMed] [Google Scholar]
  11. Story J. R., Abdulla A. M., Frank M. J. Cardiogenic shock and disopyramide phosphate. JAMA. 1979 Aug 17;242(7):654–655. [PubMed] [Google Scholar]
  12. Tavassoli M. Erythroblastemia. West J Med. 1975 Mar;122(3):194–198. [PMC free article] [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES